{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:03:22Z","timestamp":1790834602804,"version":"4.1.0"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"45","license":[{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,10]]},"abstract":"<jats:p>Treatment options for hospitalized people living with HIV\/AIDS (PLWHA) with opportunistic infections and comorbidities are limited in China. Albuvirtide (ABT), a new peptide drug, is a long-acting HIV fusion inhibitor with limited drug-drug interactions and fast onset time. This single-center, retrospective cohort study investigated the effectiveness and safety of ABT plus dolutegravir (DTG) therapy in a real-world setting. We performed a chart review on the electronic patient records for hospitalized PLWHA using ABT plus DTG between April and December 2020. The clinical outcomes were retrospectively analyzed. Among 151 PLWHA (mean age 47.6\u2009\u00b1\u200915.9 years), 140 (93%) had at least 1 episode of bacterial and\/or fungal infections and 64 (42%) had other comorbidities including syphilis, hepatitis B, and\/or hypertension. ABT plus DTG was given to 87 treatment-na\u00efve (TN) and 64 treatment-experienced (TE) PLWHA. Regardless of treatment history, mean HIV-1 RNA levels significantly decreased from 4.32 log<jats:sub>10<\/jats:sub>copies\/mL to 2.24 log<jats:sub>10<\/jats:sub>copies\/mL, 2.10 log<jats:sub>10<\/jats:sub>copies\/mL and 1.89 log<jats:sub>10<\/jats:sub>copies\/mL after 2, 4 and 8 weeks of treatment, respectively (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .0001). Compared with baseline mean CD4 + T-cell counts of 122.72 cells\/\u03bcL, it increased to 207.87 cells\/\u03bcL (<jats:italic toggle=\"yes\">P<\/jats:italic> = .0067) and 218.69 cells\/\u03bcL (<jats:italic toggle=\"yes\">P<\/jats:italic> = .0812) after 4 and 8 weeks of treatment. Except for limited laboratory abnormalities such as hyperuricemia, increased creatinine level, and hyperglycemia observed after treatment, no other clinical adverse events were considered related to ABT plus DTG. Data suggests that ABT plus DTG is safe and effective for critically-ill hospitalized PLWHA. In view of the rapid viral load suppression and restoration of CD4 + count within 8 weeks of treatment, its clinical application warrants further investigation.<\/jats:p>","DOI":"10.1097\/md.0000000000035344","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T19:09:50Z","timestamp":1699643390000},"page":"e35344","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Tolerability and effectiveness of albuvirtide combined with dolutegravir for hospitalized people living with HIV\/AIDS"],"prefix":"10.1097","volume":"102","author":[{"given":"Huanxia","family":"Liu","sequence":"first","affiliation":[{"name":"Clinical Section 1, Department of Infectious Disease, Public Health Clinical Center of Chengdu, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8380-7624","authenticated-orcid":false,"given":"Shenghua","family":"He","sequence":"additional","affiliation":[{"name":"Clinical Section 1, Department of Infectious Disease, Public Health Clinical Center of Chengdu, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongtong","family":"Yang","sequence":"additional","affiliation":[{"name":"Clinical Section 1, Department of Infectious Disease, Public Health Clinical Center of Chengdu, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunrong","family":"Lu","sequence":"additional","affiliation":[{"name":"Clinical Section 1, Department of Infectious Disease, Public Health Clinical Center of Chengdu, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Yao","sequence":"additional","affiliation":[{"name":"Clinical Section 1, Department of Infectious Disease, Public Health Clinical Center of Chengdu, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruifeng","family":"Zhou","sequence":"additional","affiliation":[{"name":"Clinical Section 1, Department of Infectious Disease, Public Health Clinical Center of Chengdu, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Yin","sequence":"additional","affiliation":[{"name":"Clinical Section 1, Department of Infectious Disease, Public Health Clinical Center of Chengdu, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanhong","family":"He","sequence":"additional","affiliation":[{"name":"Clinical Section 1, Department of Infectious Disease, Public Health Clinical Center of Chengdu, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Cheng","sequence":"additional","affiliation":[{"name":"Clinical Section 1, Department of Infectious Disease, Public Health Clinical Center of Chengdu, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/infdis\/174.4.704","article-title":"Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection AIDS Clinical Trials Group (ACTG) 116B\/117 Study Team ACTG Virology Committee Resistance and HIV-1 RNA Working Groups.","volume":"174","author":"Coombs","year":"1996","journal-title":"J Infect Dis"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1056\/NEJMe1707598","article-title":"The enduring challenge of advanced HIV infection.","volume":"377","author":"Ford","year":"2017","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"R3-20250504","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3851\/IMP1527","article-title":"Management of late-presenting patients with HIV infection.","volume":"15","author":"Rockstroh","year":"2010","journal-title":"Antivir Ther"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.1016\/S2352-3018(15)00137-X","article-title":"Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis.","volume":"2","author":"Ford","year":"2015","journal-title":"Lancet HIV"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"817","DOI":"10.7326\/0003-4819-156-11-201206050-00419","article-title":"Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel.","volume":"156","author":"Thompson","year":"2012","journal-title":"Ann Intern Med"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.chest.2019.08.002","article-title":"Critically ill patients with HIV: 40 years later.","volume":"157","author":"Azoulay","year":"2020","journal-title":"Chest"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"e0186968","DOI":"10.1371\/journal.pone.0186968","article-title":"Highly active antiretroviral therapy for critically ill HIV patients: a systematic review and meta-analysis.","volume":"12","author":"Andrade","year":"2017","journal-title":"PLoS One"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"e25449","DOI":"10.1002\/jia2.25449","article-title":"The challenge of HIV treatment in an era of polypharmacy.","volume":"23","author":"Back","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"R9-20250504","first-page":"204993612090139","article-title":"The management of treatment-experienced HIV patients (including virologic failure and switches).","volume":"7","author":"Cutrell","year":"2020","journal-title":"Ther Adv Infect Dis"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"3","DOI":"10.24875\/AIDSRev.M17000010","article-title":"Antiretroviral therapy in advanced HIV disease: which is the best regimen.","volume":"20","author":"Burgos","year":"2018","journal-title":"AIDS Rev"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1038\/s41598-018-21791-2","article-title":"Early antiretroviral therapy on reducing HIV transmission in China: strengths, weaknesses and next focus of the program.","volume":"8","author":"Liu","year":"2018","journal-title":"Sci Rep"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1473-3099(11)70097-4","article-title":"Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study.","volume":"11","author":"Zhang","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 8","key":"R13-20250504","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1097\/01.aids.0000304710.10036.2b","article-title":"The Chinese free antiretroviral treatment program: challenges and responses.","volume":"21","author":"Zhang","year":"2007","journal-title":"AIDS"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/sj.cr.7290362","article-title":"Current progress of China\u2019s free ART program.","volume":"15","author":"Zhang","year":"2005","journal-title":"Cell Res"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1098\/rsif.2012.0127","article-title":"Assessing the impact of adherence to anti-retroviral therapy on treatment failure and resistance evolution in HIV.","volume":"9","author":"Cadosch","year":"2012","journal-title":"J R Soc Interface"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12981-016-0091-1","article-title":"Combination of long-acting HIV fusion inhibitor albuvirtide and LPV\/r showed potent efficacy in HIV-1 patients.","volume":"13","author":"Zhang","year":"2016","journal-title":"AIDS Res Ther"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/00498254.2016.1166532","article-title":"Evaluation of pharmacokinetic interactions between long-acting HIV-1 fusion inhibitor albuvirtide and lopinavir\/ritonavir, in HIV-infected subjects, combined with clinical study and simulation results.","volume":"47","author":"Yang","year":"2017","journal-title":"Xenobiotica"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"e32599","DOI":"10.1371\/journal.pone.0032599","article-title":"Biophysical property and broad anti-hiv activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor.","volume":"7","author":"Chong","year":"2012","journal-title":"PLoS One"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1097\/CM9.0000000000001273","article-title":"Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study.","volume":"133","author":"Su","year":"2020","journal-title":"Chin Med J (Engl)"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1586\/14787210.1.3.389","article-title":"The role of lopinavir\/ritonavir(Kaletra\u00ae)in the management of HIV infected adults.","volume":"1","author":"Walmsley","year":"2003","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"e400","DOI":"10.1016\/S2352-3018(18)30093-6","article-title":"Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research.","volume":"5","author":"Dorward","year":"2018","journal-title":"Lancet HIV"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1007\/s40121-021-00540-5","article-title":"Tolerability and adherence of antiretroviral regimens containing long-acting fusion inhibitor albuvirtide for HIV post-exposure prophylaxis: a cohort study in China.","volume":"10","author":"Nie","year":"2021","journal-title":"Infect Dis Ther"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies.","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jinf.2022.05.034","article-title":"Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy: 48-week randomized, controlled, phase 3 non-inferiority TALENT study.","volume":"85","author":"Su","year":"2022","journal-title":"J Infect"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"104552","DOI":"10.1016\/j.antiviral.2019.104552","article-title":"Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected na\u00efve patients: results from a multicenter cohort study.","volume":"169","author":"Rossetti","year":"2019","journal-title":"Antiviral Res"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/hiv.12004","article-title":"Impact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials*.","volume":"14","author":"Stephan","year":"2013","journal-title":"HIV Med"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1093\/jac\/dkx300","article-title":"Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen.","volume":"72","author":"Raffi","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/01.aids.0000226951.49353.ed","article-title":"Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells\/microl.","volume":"20","author":"Wood","year":"2006","journal-title":"AIDS"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(02)09411-4","article-title":"Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.","volume":"360","author":"Egger","year":"2002","journal-title":"Lancet"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1086\/379201","article-title":"Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy.","volume":"188","author":"Wood","year":"2003","journal-title":"J Infect Dis"},{"key":"R33-20250504","first-page":"289","article-title":"Why are baseline HIV RNA levels 100,000 copies\/mL or greater associated with mortality after the initiation of antiretroviral therapy?","volume":"38","author":"Wood","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1007\/s00268-020-05402-8","article-title":"Perioperative antiretroviral regimen for HIV\/AIDS patients who underwent abdominal surgery.","volume":"44","author":"Yang","year":"2020","journal-title":"World J Surg"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/S0140-6736(97)10291-4","article-title":"Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease.","volume":"351","author":"Li","year":"1998","journal-title":"Lancet"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1126\/science.277.5322.112","article-title":"Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.","volume":"277","author":"Autran","year":"1997","journal-title":"Science"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1016\/S2352-3018(15)00006-5","article-title":"CD4\/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study.","volume":"2","author":"Mussini","year":"2015","journal-title":"Lancet HIV"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"e1004078","DOI":"10.1371\/journal.ppat.1004078","article-title":"HIV-infected individuals with low CD4\/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality.","volume":"10","author":"Serrano-Villar","year":"2014","journal-title":"PLoS Pathog"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035344","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:30:18Z","timestamp":1746325818000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,10]]},"references-count":36,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000035344","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,10]]}}}